Testing RSLV-132 for Sjögren's disease in women
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman diagnosed with Sjögren's disease in the last 30 years.
- You have a positive blood test for anti-Ro/SSA antibodies.
- You have at least a moderate level of Sjögren's symptoms, especially fatigue, based on a standard questionnaire.
- You agree to use highly effective birth control if you could become pregnant, or you are not able to have children.
- You have not had major changes to your Sjögren's medications in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ESG206, which is designed to calm the immune system and reduce the symptoms of Sjögren's syndrome. If you join, you may get this medicine or a placebo, and the study will see if it safely helps with things like dry eyes and dry mouth.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called JH013 for primary Sjögren's syndrome. It aims to reduce dryness and other symptoms like fatigue and joint pain, and may help people with moderate to severe disease activity.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This trial tests an experimental medication called ONO-4915 for people with primary Sjögren's disease. It aims to see if the drug can reduce dryness and other symptoms.
Hear when a new Primary Sjögren Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.